Achaogen Inc (AKAO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010840
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company is developing plazomicin for the treatment of serious bacterial infections due to MDR Enterobacteriaceae. Its pipeline products include C-scape, lpxC inhibitors, and others. Achaogen’s C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with the antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Achaogen Raises US$19 Million In Venture Financing 11
Licensing Agreements 12
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Equity Offering 14
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc – Key Competitors 23
Achaogen Inc – Key Employees 24
Achaogen Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 26
Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 32
Nov 07, 2016: Achaogen Reports Third Quarter 2016 Financial Results 34
Aug 08, 2016: Achaogen Reports Second Quarter 2016 Financial Results and Provides Corporate Update 35
May 05, 2016: Achaogen Reports First Quarter 2016 Financial Results 37
Mar 15, 2016: Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 40
Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 41
Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 42
Feb 23, 2017: Achaogen Announces Leadership Promotions 43
Jan 05, 2017: Achaogen appoints new board member 44
Jun 03, 2016: Achaogen Adds Tobin Schilke as Chief Financial Officer 45
Government and Public Interest 46
May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46
Product News 47
07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47
07/15/2016: Achaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York 48
06/20/2016: Achaogen Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens 49
06/09/2016: Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting 51
Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company’s R&D Day 52
Clinical Trials 53
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 53
Sep 01, 2016: Achaogen Completes Patient Enrollment in Phase 3 EPIC Clinical Trial of Plazomicin 54
Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin 55
Apr 05, 2016: Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin 56
Jan 11, 2016: Achaogen Announces Enrollment of First Patient in EPIC, a Phase 3 Clinical Trial for the Treatment of Complicated Urinary Tract Infections With Plazomicin 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Raises US$19 Million In Venture Financing 11
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc, Key Competitors 23
Achaogen Inc, Key Employees 24

★海外企業調査レポート[Achaogen Inc (AKAO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NOW Inc (DNOW):企業の財務・戦略的SWOT分析
    NOW Inc (DNOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Owlstone Medical Ltd:企業の製品パイプライン分析2018
    Summary Owlstone Medical Ltd (Owlstone Medical), formerly Tiger Dawn Ltd, is a diagnostic company. The company develops and commercializes breathalyzers for use in clinical diagnostics and precision medicines. It offers FAIMS Technology for medical applications; Lonestar for disease biomarker detect …
  • Neptune Technology Group Inc:企業の戦略的SWOT分析
    Neptune Technology Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Super Dragon Technology Co., Ltd. (9955):企業の財務・戦略的SWOT分析
    Super Dragon Technology Co., Ltd. (9955) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Medical Developments International Ltd (MVP):企業の財務・戦略的SWOT分析
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • Public Broadcasting Service:企業の戦略的SWOT分析
    Public Broadcasting Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Atria Plc:戦略・SWOT・企業財務分析
    Atria Plc - Strategy, SWOT and Corporate Finance Report Summary Atria Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Noble Energy, Inc.:戦略・SWOT・企業財務分析
    Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • VEON LTD. (VIP):企業の財務・戦略的SWOT分析
    VEON LTD. (VIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Baloise Belgium NV:企業の戦略・SWOT・財務分析
    Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report Summary Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sony Financial Holdings Inc.:企業の戦略・SWOT・財務情報
    Sony Financial Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sony Financial Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Jacobs Engineering Group Inc (J):企業の財務・戦略的SWOT分析
    Jacobs Engineering Group Inc (J) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Zagro Asia Ltd:企業の戦略的SWOT分析
    Zagro Asia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • China Taiping Insurance Holdings Company Limited:戦略・SWOT・企業財務分析
    China Taiping Insurance Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary China Taiping Insurance Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • OpenHydro Group Limited:電力:M&Aディール及び事業提携情報
    Summary OpenHydro Group Limited (OpenHydro) a subsidiary of DCNS S.A. designs and manufactures marine turbines for generating renewable energy from tidal streams. The company offers installation and maintenance services for the construction of tidal farms using its Open-Centre Turbine technology. It …
  • WorleyParsons Ltd (WOR):電力:M&Aディール及び事業提携情報
    Summary WorleyParsons Ltd (WorleyParsons) is a provider of professional services. Its services cover the full lifecycle, from creating new assets to sustaining and enhancing operating assets. The company provides integrated solution for deepwater developments with the associated subsea, pipelines, r …
  • Hyundai Steel Co:企業の戦略・SWOT・財務情報
    Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • DBS Bank (Hong Kong) Limited:企業の戦略・SWOT・財務情報
    DBS Bank (Hong Kong) Limited - Strategy, SWOT and Corporate Finance Report Summary DBS Bank (Hong Kong) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • DEINOVE SA (ALDEI):製薬・医療:M&Aディール及び事業提携情報
    Summary Deinove SA (Deinove) is a biotech company that discovers, develops and produces compounds. The company combines its biological assets and its metabolic engineering technology in three fields of application including healthcare, nutrition and cosmetics. Its healthcare application provides res …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆